SEARCH

SEARCH BY CITATION

Keywords:

  • tobacco;
  • smoking;
  • stomach neoplasms;
  • mortality;
  • prospective study

Abstract

  1. Top of page
  2. Abstract
  3. MATERIAL AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. POSTSCRIPT
  7. Acknowledgements
  8. REFERENCES

Cigarette smoking is associated with increased risk of stomach cancer in many studies but there are limited data on this relationship in women and on risk associated with use of tobacco products other than cigarettes. We examined stomach cancer death rates in relation to cigarette smoking in women and use of cigarette, cigar, pipe, or smokeless tobacco in men in a nationwide prospective mortality study in the United States (US). Cohort follow-up from 1982–96 identified 996 and 509 stomach cancer deaths among 467,788 men and 588,053 women, respectively. Cox proportional hazards models were fitted to estimate rate ratios (RR) and 95% confidence intervals (CI) using non-users of tobacco as the referent group. Multivariate-adjusted RRs were the highest for men who currently smoked cigars (RR = 2.29, 95% CI = 1.49–3.51) or cigarettes (RR = 2.16, 95% CI = 1.75–2.67) and both increased with smoking duration. Women who currently (RR = 1.49, 95% CI = 1.18–1.88) or formerly (RR = 1.36, 95% CI = 1.08–1.71) smoked cigarettes were at significantly increased risk, as were men who formerly smoked cigarettes (RR = 1.55, 95% CI = 1.28–1.88), or currently (RR = 1.81, 95% CI = 1.40–2.35) or formerly (RR: 1.57, 95% CI = 1.22–2.03) used more than one type of tobacco. Men who reported a history of chronic indigestion or gastroduodenal ulcer had substantially higher mortality rates associated with current cigarette (RR = 3.45, 95% CI = 2.05–5.80) or cigar (RR = 8.93, 95% CI = 4.02–19.90) smoking, as did men who were current aspirin users. If causal, the estimated proportion of stomach cancer deaths attributable to tobacco use would be 28% in US men and 14% in women. We conclude that prolonged use of tobacco products is associated with increased stomach cancer mortality in men and women. The accumulated evidence from this and other studies support reconsidering stomach cancer as a tobacco-related cancer. © 2002 Wiley-Liss, Inc.

Over 1 billion people use tobacco worldwide.1 Consumption of tobacco products is increasing in many parts of Asia, Latin America and Eastern Europe.2, 3 In the United States (US), cigar smoking and snuff dipping also have increased in recent years, especially among youth and young adults.4, 5 Tobacco is projected to be the single most important and preventable cause of disease in the world by the 2020s;6 it already is in the US and Western Europe.7 Eight cancers have been designated by the US Surgeon General to be caused by tobacco smoking.8 Stomach cancer was counted among the smoking-attributable cancers in 19879 but subsequently removed from the list due to uncertainties about causality;8 no consistent dose-response with smoking duration or intensity had been shown in studies published up to the late 1980s.10, 11

Stomach cancer is the second most common cancer globally.12, 13 The highest risk is seen in areas of the world where chronic infection with the bacterium Helicobacter (H.) pylori remains endemic.14, 15, 16 If tobacco use causes stomach cancer, then the emerging and maturing tobacco epidemic in intermediate- to high-risk areas for stomach cancer will likely contribute to substantial increases in stomach cancer incidence and mortality worldwide.

In the US, overall rates of stomach cancer have decreased during the past century, coincident with a decline in the prevalence of H. pylori infection and other important risk factors.15, 16 Since the 1970s, however, incidence of adenocarcinomas of the gastric cardia has increased rapidly.17, 18 These tumors now represent nearly half of all stomach cancers in US men16, 17 and appear not to be H. pylori-related.14, 15, 19, 20 Prolonged cigarette smoking has been postulated to contribute to the increase in gastric cardia adenocarcinomas in the US and Western Europe, reflecting a lag time of 30 or more years between tobacco use and clinical disease.21

Cigarette smoking has been positively associated with stomach cancer incidence and mortality in prospective22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32 and case-control studies33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56 of men, although not all studies have found such an association57, 58, 59, 60, 61, 62, 63, 64 and not all positive studies have observed a consistent dose-response relationship with smoking duration or intensity. Prospective studies of women in Scandinavia have not found a positive association28, 58, 59 and results from case-control studies of women have been inconsistent.37, 40, 47, 51, 52 Most published studies, especially prospective studies, have not adjusted for potentially important covariates such as socioeconomic status, dietary factors, or H. pylori infection.65, 66 Data on the use of cigar, pipe, or smokeless tobacco in relation to stomach cancer are limited. Only a few studies have stratified the analyses by H. pylori infection status.

We examined stomach cancer mortality in relation to the use of 4 types of tobacco products (cigarettes, cigars, pipe and smokeless tobacco including chewing tobacco and snuff) in men and cigarette smoking in women in the Cancer Prevention Study II (CPS II) prospective cohort, adjusting for multiple potential confounding factors.

MATERIAL AND METHODS

  1. Top of page
  2. Abstract
  3. MATERIAL AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. POSTSCRIPT
  7. Acknowledgements
  8. REFERENCES

Study population

CPS II is a prospective mortality cohort established by the American Cancer Society (ACS) in 1982, with 508,351 men and 676,306 women recruited by ACS volunteers in 50 states, the District of Columbia and Puerto Rico. To be eligible for the study, individuals had to be age 30 years or older and reside in a household in which at least 1 person was age 45 years or older. Median age at cohort entry was 57 years for men and 56 years for women.

This analysis is based on 14 years of cohort follow-up from study enrollment in 1982 to December 31, 1996. Vital status of study participants was obtained by ACS volunteers in 1984, 1986 and 1988; reported deaths were verified with death certificates. Since 1988, vital status has been ascertained via automated linkage of the CPS II study population with the National Death Index (NDI) for date and, since 1993, cause of death.67 The underlying cause of death, from death certificate or NDI, was classified according to the International Classification of Disease (ICD), 9th Revision.68 Our outcome of interest was death due to stomach cancer (ICD-9 codes 151.0–151.9). As of December 31, 1996, 129,642 men and 107,810 women had died and 2,897 (0.24%) individuals had follow-up truncated in 1988 due to insufficient information for NDI linkage. We excluded from this analysis individuals who reported a previous cancer (other than non-melanoma skin) at cohort enrollment (25,242 men and 57,107 women) and those with missing or uninterpretable tobacco use information (15,321 men and 31,146 women). The final analytic cohort after exclusions consisted of 467,788 men and 588,053 women and 996 and 509 deaths from stomach cancer, respectively.

Tobacco use information

At enrollment in 1982, study participants completed a questionnaire that included questions on current and past use of multiple types of tobacco products in men (cigarettes, cigars, pipes, chewing tobacco and snuff) and cigarettes in women. CPS II men were grouped into never, current and former users of each type of tobacco at enrollment. Due to small numbers, men who exclusively chewed tobacco or used snuff were grouped together as smokeless tobacco users. Men who reported having used more than one type of tobacco were considered separately as current users if they reported using any tobacco product at enrollment. Lifelong non-users of any tobacco were the referent group for all analyses.

Smokers of exclusively cigarettes or cigars were further characterized by years of use, average number of cigarettes or cigars smoked per day, age started smoking, depth of cigar smoke inhalation (do not inhale to inhale deeply) and, among former smokers, age quit smoking and number of years since quit. Categories with <20 stomach cancer deaths (pipe and smokeless tobacco) were not examined beyond status of use. Current and former users of more than one type of tobacco were characterized by the number of years between first and last use of any tobacco, number of years since first use and, among former users, age quit using any tobacco and the number of years since quit. CPS II women were grouped into never, current and former cigarette smokers at enrollment, with smoking characteristics examined similarly as men.

Covariate information

Potential confounders were chosen based on their observed association with stomach cancer mortality69, 70 and with tobacco use in CPS II and on stomach cancer risk factors reported in the literature.71, 72 Covariates included in final multivariate models were age (single year), race (white, black, other, or unspecified), education (some high school, high school graduate, some college or trade school, college graduate or post-graduate work, or unspecified), family history of stomach cancer among first degree relatives (yes, no), intake of high-fiber grain foods (in quintiles) and vegetables (in quintiles), consumption of citrus fruits or juices (in tertiles), a variable combining supplemental vitamin C use frequency (never, occasional, 1–29 per month, 30+ per month, or unspecified) and duration (never, 1–3 years, 4–9 years, or 10+ years), a variable combining supplemental multivitamin use frequency (never, occasional, 1–29 per month, or 30+ per month) and duration (never, 1–4 years, 5–9 years, or 10+ years) and a variable combining aspirin use frequency (never, occasional, 1–14 per month, 15+ per month, or unspecified) and duration (never, 1–9 years, 10–19 years, 20+ years, or unspecified).

The diet section of the questionnaire included 32 foods and 10 beverages. Food intake variables were derived by summing the number of days per week that each participant reported consuming each vegetable (carrots, tomatoes, potatoes, squash/corn, green leafy vegetables, raw vegetables, cabbage/broccoli/Brussels sprouts), high-fiber grain foods (bran/corn muffins, brown rice/whole wheat/barley and oatmeal/shredded wheat/bran cereals) and citrus fruits or juices.

The following variables were also evaluated as potential confounders: body mass index, exercise, alcohol consumption, own or parents' country of birth (as a crude proxy for early childhood exposures such as socioeconomic status or H. pylori) and personal history of chronic indigestion or gastroduodenal ulcer. None of these materially altered risk estimates associated with tobacco use and thus were not included in final multivariate models. These variables were evaluated as potential effect modifiers, as were family history of stomach cancer and aspirin use.

Statistical methods

Age-adjusted stomach cancer mortality rates were directly standardized to the age distribution of the 1970 world population age 30 years and over. Maximum likelihood estimates of rate ratios (RR) and 95% confidence intervals (CI) were obtained by fitting Cox proportional hazards models73 using lifelong nonusers of tobacco as the referent group. p-Values for trend were estimated by modeling tobacco use characteristics as continuous variables, excluding lifelong nonusers.74 The Wald statistic was used to test for homogeneity of stratum-specific rate ratios75 in analyses stratified by covariates. The proportion of stomach cancer deaths attributable to tobacco use in the population was estimated based on CPS II multivariate-adjusted RRs associated with ever use of any tobacco product and prevalence estimates of any tobacco (cigarette, cigar, pipe, or smokeless tobacco) use in US adult men and cigarette smoking women in 1991.4 All analyses were carried out with the SAS software package;76 all statistical tests were 2-sided.

RESULTS

  1. Top of page
  2. Abstract
  3. MATERIAL AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. POSTSCRIPT
  7. Acknowledgements
  8. REFERENCES

Patterns and correlates of tobacco use

Seventy-five percent of CPS II men reported ever using any tobacco product; 32% were current and 38% former users of at least one tobacco product at enrollment, 5% were ever users with incomplete information. Twenty percent of men were current and 27% former smokers of exclusively cigarettes, less than 2% currently and exclusively smoked cigars. Seventeen percent of men reported having used more than one type of tobacco in their lifetime; of these, over 61% reported smoking cigarettes in combination with cigars or pipe, 25% smoked cigarettes and used smokeless tobacco and 14% used smokeless tobacco and smoked cigars or pipe. Nearly 21% of women were current cigarette smokers and another 21% former smokers in 1982.

Current users of any tobacco were more likely to report low or no intake of high-fiber grain foods, vegetables and citrus fruits or juices compared to lifelong non-users (Table I). With the exception of pipe smokers, male current users of tobacco products were less likely to report education beyond high school compared to non-users. Men who currently used any tobacco were less likely to take supplemental vitamin C or multivitamins than never or former users. Women who quit smoking cigarettes reported higher educational attainment and higher intake of high-fiber grain foods, vegetables and citrus fruits or juices compared to never- or current-smoking women; they were also more likely to report current use of supplemental vitamin C, multivitamins, or aspirin. Women who were current cigarette smokers were less likely to report consumption of high-fiber grain foods, vegetables and citrus fruits or juices than never- or former-smokers.

Table I. Study Participant Characteristics by Selected Tobacco Use Status at Study Baseline1
Tobacco use statusTotal nRace: non-whiteHigh school graduate or lessFamily history of stomach cancerLow or no intake of vegetablesLow or no intake of citrus fruits or juicesNo intake of high-fiber grain foodsCurrent user of multi-vitaminsCurrent user of vitamin C supplementCurrent use of aspirin (≥15/month)
  • 1

    CPS II men and women, 1982. Data in %.

Men          
 Never user117,968630415241831257
 Current cigarette only93,468841322403027197
 Current cigar only6,945635421292725187
 Current pipe only8,460426316272129217
 Current chewing tobacco or snuff2,855666424392621167
 Current user, >1 type of tobacco39,678444418352427209
 Former cigarette only126,6044344152821302310
 Former user, >1 type of tobacco40,5903284132416342711
Women          
 Never smoker326,835746319281836268
 Current cigarette122,465845323382536258
 Former cigarette122,4555343142616423110

Stomach cancer mortality by type of tobacco use

Ever users of any tobacco product were at significantly higher risk of stomach cancer death compared to never users (multivariate-adjusted RR = 1.68, 95% CI = 1.42–1.98 for men and RR = 1.38, 95% CI = 1.15–1.65 for women); risk estimates for current use were consistently higher than those for former use (Table II). Men who currently smoked cigars (RR = 2.29, 95% CI = 1.49–3.51) or cigarettes (RR = 2.16, 95% CI = 1.75–2.67) were at the highest risk of stomach cancer death, followed by men who formerly smoked cigarettes (RR = 1.55, 95% CI = 1.28–1.88) and currently (RR = 1.81, 95% CI = 1.40–2.35) or formerly (RR = 1.57, 95% CI = 1.22–2.03) used more than one type of tobacco. Current pipe smokers, users of smokeless tobacco and former cigar smokers had smaller increases in risk. Women who currently (RR = 1.49, 95% CI = 1.18–1.88) or formerly (RR = 1.36, 95% CI = 1.08–1.71) smoked cigarettes had significantly higher stomach cancer mortality compared to women who never smoked. Adjustment for multiple covariates somewhat elevated RRs in former users and slightly reduced the RRs but did not eliminate the statistically significant increased risk in current users.

Table II. Stomach Cancer Mortality Rates1
Type of tobacco useNumber of study participantsPerson-yearsStomach cancer deathsMortality rate per 100,0002Age-adjusted RR (95% CI)Multivariate-adjusted RR (95% CI)3
  • 1

    Age- and multivariate-adjusted mortality rate ratios (RR) and 95% confidence intervals (CI) by tobacco use status at study baseline, CPS II men and women, 1982 through 1996.

  • 2

    Mortality rates directly standardized to the 1970 world population of men and women age 30 years and over.

  • 3

    Multivariate models include age, race, education, family history of stomach cancer, consumption of high-fiber grain foods, vegetables, citrus fruits or juices, and use of vitamin C, multivitamins, and aspirin.

  • 4

    Mortality rates not provided for categories with fewer than 20 stomach cancer deaths.

MEN467,7885,980,0519967.1  
 Never-user of any type of tobacco117,9681,558,5521695.21.00 (Referent)1.00 (Referent)
 Ever-user of any type of tobacco349,8204,421,4998277.61.73 (1.47–2.04)1.68 (1.42–1.98)
  Current user of any type of tobacco151,4061,903,5153758.72.12 (1.76–2.54)1.97 (1.64–2.37)
   Current-cigarette only93,4681,166,2802309.62.41 (1.96–2.96)2.16 (1.75–2.67)
   Current-cigar only6,94590,4352510.72.47 (1.62–3.78)2.29 (1.49–3.51)
   Current-pipe only48,460110,34116 1.30 (0.78–2.18)1.33 (0.80–2.23)
   Current-chewing tobacco/snuff only42,85535,6738 1.79 (0.88–3.65)1.58 (0.76–3.28)
   Current->1 type of tobacco39,678500,785968.31.85 (1.44–2.38)1.81 (1.40–2.35)
  Former user of any type of tobacco179,8332,298,1244006.91.49 (1.24–1.78)1.51 (1.26–1.81)
   Former-cigarette only126,6041,618,0132857.11.56 (1.29–1.89)1.55 (1.28–1.88)
   Former-cigar only45,83473,74413 1.25 (0.71–2.19)1.28 (0.72–2.25)
   Former-pipe only45,92478,0286 0.64 (0.29–1.45)0.70 (0.31–1.60)
   Former-chewing tobacco/snuff only488110,8122 1.21 (0.30–4.92)1.11 (0.27–4.50)
   Former->1 type of tobacco40,590517,527945.61.44 (1.12–1.85)1.57 (1.22–2.03)
  Ever-user, incomplete information18,581219,860529.81.65 (1.21–2.26)1.52 (1.10–2.10)
WOMEN588,0537,913,5435092.6  
 Never smoked cigarettes326,8354,404,9442822.31.00 (Referent)1.00 (Referent)
 Ever smoked cigarettes261,2183,508,5992273.01.34 (1.12–1.60)1.38 (1.15–1.65)
  Current-cigarette only122,4651,629,2961053.21.51 (1.20–1.90)1.49 (1.18–1.88)
  Former-cigarette only122,4551,665,4261063.01.26 (1.01–1.59)1.36 (1.08–1.71)
  Ever smoker, incomplete information416,298213,87716 1.16 (0.70–1.92)1.10 (0.67–1.83)

Stomach cancer mortality rates by birth year and tobacco use

Among men, age-specific death rates from stomach cancer were higher at all ages in current users of any tobacco at the time of enrollment than in lifelong non-users of tobacco and higher in men born in earlier calendar years (Fig. 1). The patterns among women were similar but less stable due to small numbers (data not shown).

thumbnail image

Figure 1. Age-specific stomach cancer death rates by tobacco use status at study enrollment and birth year, CPS II men, 1982 to 1996

Download figure to PowerPoint

Dose-response analysis

Among current cigarette smokers (Table III), the multivariate-adjusted RRs increased with smoking duration (men, p-trend = 0.059), average number of cigarettes smoked per day (women, p-trend = 0.038), younger age at smoking initiation (men, p-trend = 0.075) and with pack-years (women, p-trend = 0.053). In currently smoking men, the RR estimates increased with number of cigarettes smoked per day except in the highest category of 2 or more packs per day.

Table III. Dose-Response Gradients in Current Smokers of Exclusively Cigarettes1
 MenWomen
nAge-adjusted RR (95% CI)Multivariate-adjusted RR (95% CI)2nAge-adjusted RR (95% CI)Multivariate-adjusted RR (95% CI)2
  • 1

    Number of stomach cancer deaths (n), age- and multivariate-adjusted rate ratios (RR) and 95% confidence intervals (CI), CPS II men and women, 1982 through 1996.

  • 2

    Multivariate models include age, race, education, family history of stomach cancer, consumption of high-fiber grain foods, vegetables, citrus fruits or juices, and use of vitamin C, multivitamins, and aspirin.

  • 3

    Estimates of p trend excluded non-users of tobacco.

Never user1691.00 (Referent)1.00 (Referent)2821.00 (Referent)1.00 (Referent)
Cigarette smoker2302.41 (1.96–2.96)2.16 (1.75–2.67)1051.51 (1.20–1.90)1.49 (1.18–1.88)
Years smoked cigarettes
 <2041.34 (0.46–3.91)1.17 (0.40–3.37)71.53 (0.72–3.26)1.43 (0.67–3.04)
 20–2991.08 (0.53–2.20)0.97 (0.48–1.98)141.26 (0.72–2.22)1.23 (0.70–2.17)
 30–39672.23 (1.62–3.06)2.08 (1.51–2.87)391.83 (1.28–2.61)1.84 (1.29–2.64)
 ≥401282.58 (2.04–3.28)2.36 (1.84–3.02)351.43 (1.00–2.04)1.47 (1.02–2.10)
 p trend3 0.04820.0589 0.14930.0743
Cigarettes smoked per day
 <20512.00 (1.46–2.74)1.66 (1.21–2.29)391.35 (0.97–1.90)1.31 (0.93–1.84)
 20 (1 pack)812.83 (2.16–3.70)2.51 (1.90–3.31)281.26 (0.85–1.86)1.25 (0.84–1.85)
 21–39562.75 (2.02–3.75)2.73 (1.99–3.75)182.05 (1.26–3.32)2.15 (1.32–3.50)
 ≥40 (≥2 packs)351.89 (1.30–2.74)1.83 (1.25–2.67)122.11 (1.17–3.78)2.15 (1.20–3.87)
 p trend3 0.79040.5392 0.07850.0375
Age started smoking cigarettes, years
 ≤15562.50 (1.84–3.39)2.17 (1.58–2.98)101.67 (0.88–3.15)1.56 (0.83–2.96)
 16–191092.61 (2.03–3.34)2.41 (1.87–3.11)431.62 (1.16–2.26)1.63 (1.17–2.28)
 ≥20552.01 (1.48–2.73)1.85 (1.36–2.53)521.50 (1.11–2.03)1.49 (1.10–2.01)
 p trend3 0.03060.0747 0.74040.6715
Pack-years
 ≤19211.71 (1.08–2.70)1.42 (0.89–2.26)261.61 (1.07–2.42)1.56 (1.04–2.35)
 20–39492.20 (1.59–3.05)1.97 (1.42–2.74)261.24 (0.82–1.87)1.26 (0.83–1.90)
 40–59742.85 (2.15–3.77)2.69 (2.02–3.58)161.16 (0.70–1.92)1.20 (0.72–2.00)
 ≥60572.14 (1.57–2.90)2.08 (1.52–2.84)202.73 (1.73–4.31)2.84 (1.79–4.51)
 p trend3 0.76130.4011 0.10100.0528

Among men who quit smoking cigarettes (Table IV), stomach cancer death rates consistently and significantly increased with smoking duration (p-trend = 0.002), cigarettes smoked per day (p-trend = 0.064) and pack-years of smoking (p-trend = 0.004) and decreased with years since smoking cessation (p-trend = 0.002); these trends were not seen in women who quit smoking. Although the proportion of men and women who had smoked more than 1 pack of cigarettes per day decreased with more years since quit smoking, results for smoking duration and time since cessation were not substantially different when controlling for smoking intensity (data not shown).

Table IV. Dose-Response Gradients Among Former Smokers of Exclusively Cigarettes1
 MenWomen
nAge-adjusted RR (95% CI)Multivariate-adjusted RR (95% CI)2nAge-adjusted RR (95% CI)Multivariate-adjusted RR (95% CI)2
  • 1

    Number of stomach cancer deaths (n), age- and multivariate-adjusted rate ratios (RR) and 95% confidence intervals (CI), CPS II men and women, 1982 through 1996.

  • 2

    Multivariate models include age, race, education, family history of stomach cancer, consumption of high-fiber grain foods, vegetables, citrus fruits or juices, and use of vitamin C, multivitamins, and aspirin.

  • 3

    Estimates of p trend excluded non-users of tobacco.

  • 4

    Two highest categories in women grouped together due to small numbers.

Never smoker1691.00 (Referent)1.00 (Referent)2821.00 (Referent)1.00 (Referent)
Cigarette smokers2851.56 (1.29–1.89)1.55 (1.28–1.88)1061.26 (1.01–1.59)1.36 (1.08–1.71)
Years smoked cigarettes
 <20571.07 (0.79–1.45)1.10 (0.81–1.50)361.25 (0.88–1.78)1.37 (0.96–1.96)
 20–29731.52 (1.15–2.01)1.54 (1.17–2.03)271.56 (1.05–2.33)1.72 (1.15–2.57)
 30–39741.73 (1.32–2.28)1.71 (1.30–2.26)281.10 (0.74–1.62)41.19 (0.81–1.77)4
 ≥40622.10 (1.56–2.83)2.03 (1.50–2.74)   
 p trend3 0.00050.0017 0.34990.3208
Cigarettes smoked per day
 <20601.32 (0.98–1.77)1.29 (0.96–1.73)511.11 (0.82–1.50)1.19 (0.88–1.62)
 20 (1 pack)971.60 (1.25–2.06)1.60 (1.24–2.06)271.43 (0.96–2.12)1.52 (1.02–2.27)
 21–39421.56 (1.11–2.19)1.61 (1.14–2.26)171.43 (0.87–2.34)41.55 (0.95–2.55)4
 ≥40 (≥2 Packs)761.84 (1.40–2.41)1.84 (1.40–2.42)   
 p trend3 0.07680.0644 0.19460.1651
Age started smoking cigarettes, years
 ≤15441.34 (0.96–1.86)1.27 (0.91–1.78)50.85 (0.35–2.06)0.88 (0.36–2.14)
 16–191331.56 (1.24–1.97)1.55 (1.23–1.96)401.17 (0.83–1.64)1.28 (0.91–1.80)
 ≥201051.67 (1.31–2.13)1.70 (1.33–2.17)591.41 (1.06–1.86)1.51 (1.14–2.01)
 p trend3 0.87700.6079 0.48720.6052
Pack-years
 ≤19641.13 (0.85–1.51)1.14 (0.86–1.53)501.29 (0.95–1.74)1.40 (1.03–1.91)
 20–39841.62 (1.25–2.11)1.63 (1.25–2.13)191.25 (0.78–1.99)1.36 (0.85–2.18)
 40–59521.86 (1.36–2.55)1.87 (1.37–2.56)121.12 (0.63–2.00)41.21 (0.67–2.16)4
 ≥60561.95 (1.44–2.64)1.94 (1.43–2.64)   
 p trend3 0.00320.0037 0.83610.8279
Age quit smoking cigarettes
 ≤30281.13 (0.75–1.69)1.15 (0.77–1.72)151.01 (0.60–1.72)1.11 (0.65–1.89)
 31–40541.23 (0.90–1.67)1.25 (0.92–1.70)291.69 (1.14–2.49)1.83 (1.24–2.72)
 41–50841.62 (1.25–2.11)1.62 (1.24–2.10)231.18 (0.77–1.82)1.27 (0.83–1.95)
 ≥511151.94 (1.52–2.47)1.88 (1.47–2.40)361.20 (0.85–1.71)1.28 (0.90–1.82)
 p trend3 0.00060.0015 0.84640.6833
Number of years since smoking cessation
 ≤101051.99 (1.56–2.55)1.92 (1.50–2.47)341.25 (0.87–1.79)1.31 (0.91–1.87)
 11–19861.65 (1.27–2.15)1.64 (1.26–2.14)311.35 (0.93–1.97)1.46 (1.00–2.13)
 ≥20901.21 (0.93–1.56)1.23 (0.95–1.59)381.22 (0.87–1.71)1.34 (0.95–1.89)
 p trend3 0.00060.0015 0.84640.6833

Current cigar smokers had significantly higher stomach cancer death rates than non-users of tobacco, with risk consistently increasing with smoking duration and number of cigars smoked per day (Table V). Smokers of 5 or more cigars per day (RR = 4.20, 95% CI = 2.32–7.60) and those who inhaled (RR = 3.93, 95% CI = 1.92–8.04) were at particularly high risk. There were too few stomach cancer deaths among former cigar smokers to conduct detailed analyses in that group.

Table V. Dose-Response Gradients Among Current Smokers of Exclusively Cigars1
 nAge-adjusted RR (95% CI)Multivariate-adjusted RR (95% CI)2
  • 1

    Number of stomach cancer deaths (n), age- and multivariate-adjusted ratios (RR) and 95% confidence intervals (CI), CPS II men, 1982 through 1996.

  • 2

    Multivariate models include age, race, education, family history of stomach cancer, consumption of high-fiber grain foods, vegetables, citrus fruits or juices, and use of vitamin C, multivitamins, and aspirin.

  • 3

    Estimates of p trend excluded non-users of tobacco.

Never user1691.00 (Referent)1.00 (Referent)
Cigar smokers252.47 (1.62–3.78)2.29 (1.49–3.51)
Years of smoking cigars
 ≤39132.54 (1.43–4.49)2.42 (1.36–4.28)
 ≥40102.77 (1.43–5.36)2.55 (1.32–4.94)
 p trend3 0.07880.1020
Cigars smoked per day
 1–4131.79 (1.01–3.18)1.68 (0.95–2.97)
 ≥5124.57 (2.54–8.22)4.20 (2.32–7.60)
 p trend3 0.74560.5880
Age started smoking cigars, years
 ≤1962.78 (1.23–6.28)2.47 (1.09–5.61)
 20–29123.01 (1.65–5.49)2.85 (1.56–5.19)
 ≥3051.74 (0.71–4.24)1.62 (0.67–3.97)
 p trend3 0.61650.5889
Inhalation
 Do not inhale152.21 (1.29–3.78)2.08 (1.22–3.57)
 Inhale slightly-deeply84.42 (2.17–9.00)3.93 (1.92–8.04)

Use of more than one type of tobacco

Men who reported currently using more than one type of tobacco had significantly higher stomach cancer death rates than non-users of tobacco and RR's increased with the number of years between first and last use of any tobacco product; the multivariate RR (95% CI) was 1.90 (1.20–3.02) for 30–39 years and 1.80 (1.33–2.43) for 40 years or more between first and last use. Men who had quit using any tobacco product at study enrollment were also at substantially increased risk with 40 or more years between first and last use of any tobacco (RR = 2.17, 95% CI = 1.47–3.20).

Tobacco use stratified by covariates, effect modification

Stomach cancer death rate ratios associated with cigarette or cigar smoking, or with use of more than one type of tobacco, were significantly higher (test for homogeneity p-value < 0.05) among men reporting a personal history of chronic indigestion or gastroduodenal ulcer than men without such history and higher among current aspirin users than non-users (Table VI). The increase in stomach cancer mortality associated with smoking duration was significantly greater among cigarette smoking men with a personal history of chronic indigestion or gastroduodenal ulcer than men without such history and higher among current aspirin users than non-users (data not shown). No effect modification was observed with consumption of vegetables, citrus fruits or juices, or alcohol in either gender.

Table VI. Tobacco Use Stratified by Selected Covariates1
 MenWomen
Current cigarette smokersFormer Cigarette smokersCurrent cigar smokersCurrent users of >1 type of tobaccoCurrent cigarette smokersFormer cigarette smokers
nRR (95% CI)nRR (95% CI)nRR (95% CI)nRR (95% CI)nRR (95% CI)nRR (95% CI)
  • 1

    Number of stomach cancer deaths (n), multivariate-adjusted rate ratios (RR) and 95% confidence interval (CI), CPS II men and women, 1982 through 1996. Multivariate models include age, race, education, family history of stomach cancer, consumption of high-fiber grain foods, vegetables, citrus fruits or juices, and use of vitamin C, multivitamins, and aspirin.

  • 2

    p-value for test of homogeneity across strata based on the Wald statistic, only p < 0.05 are noted.

  • 3

    Excluding persons with no information on birthplace.

Never user1691.00 (Referent)1691.00 (Referent)1691.00 (Referent)1691.00 (Referent)2821.00 (Referent)2821.00 (Referent)
Tobacco use2302.16 (1.75–2.67)2851.55 (1.28–1.88)252.29 (1.49–3.51)961.81 (1.40–2.35)1051.49 (1.18–1.88)1061.36 (1.08–1.71)
Personal history of chronic indigestion or gastroduodenal ulcer
 None1671.92 (1.52–2.42)2091.36 (1.10–1.68)161.59 (0.94–2.69)671.52 (1.13–2.04)891.47 (1.15–1.90)971.44 (1.13–1.83)
 Yes633.45 (2.05–5.80)762.62 (1.58–4.34)98.93 (4.02–19.9)293.45 (1.93–6.20)161.56 (0.85–2.86)90.87 (0.42–1.83)
 p homogeneity2 0.0419 0.0182 0.0003 0.0141    
Current aspirin use
 No1241.69 (1.27–2.25)1541.25 (0.96–1.63)102.23 (1.28–3.88)561.30 (0.90–1.89)471.60 (1.17–2.18)541.39 (1.01–1.92)
 Yes1062.79 (2.06–3.77)1311.95 (1.47–2.60)152.35 (1.21–4.57)402.50 (1.75–3.57)581.38 (0.98–1.93)521.32 (0.96–1.82)
 p homogeneity2 0.0187 0.0238   0.0132    
Family history of stomach cancer
 No2172.11 (1.69–2.62)2711.54 (1.26–1.87)232.18 (1.40–3.40)871.71 (1.31–2.24)991.50 (1.18–1.91)1001.38 (1.09–1.75)
 Yes133.53 (1.40–8.89)141.82 (0.74–4.53)24.92 (1.01–23.9)94.27 (1.58–11.5)61.35 (0.54–3.35)61.12 (0.45–2.79)
Own or parents' birthplace3
 US or Canada1732.50 (1.93–3.23)2021.82 (1.43–2.32)111.74 (0.92–3.26)752.13 (1.57–2.90)721.39 (1.05–1.83)791.42 (1.09–1.86)
 Other521.56 (1.07–2.26)791.13 (0.81–1.57)132.70 (1.47–4.94)201.38 (0.83–2.29)331.76 (1.17–2.65)271.09 (0.70–1.69)
Alcohol
 Non-drinker942.12 (1.59–2.84)1291.60 (1.23–2.07)91.98 (1.00–3.93)381.55 (1.06–2.27)581.56 (1.16–2.11)591.50 (1.12–2.01)
 Drinker1362.10 (1.55–2.86)1561.48 (1.11–1.99)162.44 (1.40–4.24)581.99 (1.38–2.86)471.39 (0.95–2.04)471.19 (0.81–1.74)

Attributable fraction in the population

Assuming that the multivariate-adjusted RR's from our study represent a causal relationship with tobacco and using prevalence estimates of tobacco use from the 1991 National Health Interview Survey,4 we estimated the proportion of stomach cancer deaths in the US population attributable to ever use of any tobacco to be 28% in men and 14% in women, with the majority of deaths attributable to continuing use. In men, nearly 25% of stomach cancer deaths could be attributed to current cigarette smoking, over 5% to current cigar smoking and 4% to current smokeless tobacco use.

DISCUSSION

  1. Top of page
  2. Abstract
  3. MATERIAL AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. POSTSCRIPT
  7. Acknowledgements
  8. REFERENCES

Results from this large prospective study strongly support a causal role for tobacco use in the development of stomach cancer. Stomach cancer death rates were consistently highest in men and women who currently used any tobacco product, intermediate in former users and lowest in never-users. Significant increases in risk were associated with use of different tobacco products in men and with cigarette smoking in women. The magnitude of the increased risk was similar in men who smoked cigarettes or cigars and increased with smoking duration and intensity. CPS II is the first US prospective study to report a positive association between cigarette smoking and stomach cancer death in women.

Three prospective studies28, 58, 59 of women in Scandinavia reported no association between cigarette smoking and stomach cancer mortality or incidence. All 3 cohorts, however, combined yielded a sample size less than 20% of the CPS II female cohort and women in one of these studies28 were substantially younger than those in CPS II. Case-control studies21, 33, 35, 38, 41, 42, 46, 48, 50 have generally reported risk estimates for both sexes combined. Only 5 case-control studies37, 40, 47, 51, 52 have reported risk estimates separately for women; 3 such studies published in the 1990s from the US,40 Japan,51 and Poland52 reported significantly increased risk associated with current cigarette smoking.

Few studies have reported on cigar, pipe, or smokeless tobacco use in relation to stomach cancer and not all of these studies have excluded users of other tobacco products from the referent group. In CPS II, current smokers of exclusively cigars, even men who reported no inhalation, had significantly higher stomach cancer mortality than non-users of any tobacco. The lack of a significant trend associated with cigar smoking duration may relate to the fact that cigar smoking may be initiated at any age throughout adulthood,77 whereas cigarette smoking begins primarily before age 25 years. The comparable magnitude of increased risk of stomach cancer death in current smokers of cigars or cigarettes resembles the relationship between these products and oral and esophageal cancers,78 reflecting the tendency of cigar smokers to swallow particles of tobacco leaf and dissolved constituents of smoke, thus directly exposing oral and gastrointestinal tissues to tobacco carcinogens.78

Snuff and chewing tobacco also can be swallowed with saliva and come in direct contact with gastric mucosa. Although 3 Swedish studies42, 50, 55 have reported no association between snuff dipping and stomach cancer incidence, only 1 study50 explicitly excluded users of other tobacco products from its referent group. Snuff production in Sweden involves heat processing rather than curing and fermentation as is done in the US.55 Fermentation increases N-nitrosation of nicotine and may account for the markedly higher (up to 250-fold) amounts of tobacco-specific N-nitrosamines and volatile N-nitrosamines found in US moist snuff compared to European snuff.79, 80 Levels of hemoglobin adducts of tobacco-specific N-nitrosamine metabolites have been shown to be higher in US snuff dippers than even tobacco smokers.81

The strength of association between cigarette smoking and stomach cancer has been stronger in studies published since 1990 than in studies published previously. Earlier studies showed relative risk estimates of approximately 1.5,22, 23, 24, 33, 34, 35 whereas the majority of prospective25, 26, 27, 28, 31 and case-control studies21, 36, 37, 40, 41, 42, 43, 45, 46, 49, 51, 52, 53, 54 published since 1990 report current cigarette smoking risk estimates of 2.0 or greater. Current cigarette smoking risk estimates in case-control studies21, 40, 45, 53, 56 have also been consistently higher for gastric cardia than non-cardia adenocarcinomas.

Several studies,21, 25, 29, 31, 42, 48, 49, 53 including CPS II, show that the relative risk estimates associated with current smoking steadily increases with the number of cigarettes smoked per day up to the highest exposure category, but decreases in the highest category. This lack of a sustained linear trend in risk with smoking intensity may relate in part to the decreased tolerance of people who develop chronic atrophic gastritis, intestinal metaplasia, or gastroduodenal ulcers to continued or heavy smoking. Risk estimates increased consistently with smoking intensity among CPS II men who had quit smoking cigarettes (p-trend = 0.002) and were markedly higher among former smokers who reported a history of chronic indigestion or gastroduodenal ulcers. The inconsistent dose-response relationship in the literature also may reflect the topographic and histologic heterogeneity of stomach cancer cases in different studies; the association with tobacco use may differ by tumor type. Nevertheless, CPS II and nearly all case-control studies published since 199021, 42, 47, 48, 49, 50, 52, 53, 56 show increasing risk of stomach cancer with cigarette smoking duration. CPS II data in men further show significantly decreasing trend in risk with more years since smoking cessation.

CPS II is the only prospective study that has adjusted risk estimates for potential confounders including education, consumption of fruits and vegetables and intake of supplemental vitamin C and multivitamins. Adjustment for these covariates had little effect on the significantly increased risk estimates associated with tobacco use. One study82 has adjusted directly for H. pylori infection; this study reported a statistically significant odds ratio of 2.2 for current cigarette smoking, nearly identical to the results of CPS II and other studies unadjusted for H. pylori infection.

The association between stomach cancer death and cigarette or cigar smoking in CPS II men was significantly modified by a personal history of chronic indigestion or gastroduodenal ulcer. Because these conditions are strongly associated with chronic and recurrent H. pylori infection,14, 16 we hypothesize that H. pylori and tobacco smoke may act together to increase the risk of stomach cancer. Nicotine has been shown to potentiate the effect of H. pylori by increasing vacuolating toxin activity in cells.83 Among patients with H. pylori-associated gastritis, smokers have greater gastric chemokine mRNA expression, leading to more severe gastritis, than non-smokers.84 Smokers with chronic atrophic gastritis are consistently more likely than non-smokers to progress to intestinal metaplasia or dysplasia.85, 86, 87, 88 Although we had no data on H. pylori infection, 2 case-control studies53, 82 have reported higher cigarette smoking OR among H. pylori infected than non-infected gastric cancer cases. Our finding of a significantly stronger association between cigarette smoking and stomach cancer death in current aspirin users suggests that tobacco smoke and nicotine may exacerbate existing gastric mucosal lesions or interfere with wound healing response of the gastric mucosa to injury.89

It is biologically plausible that tobacco products play a causal role in gastric carcinogenesis at both early and late stages, possibly with decades between exposure and clinical disease. Tobacco products contain a myriad of carcinogens associated with gastric adenocarcinoma in experimental animals and humans.79, 90, 91 These carcinogens have direct contact with stomach mucosa when swallowed with saliva or bronchial secretions, as well as indirect exposure via the bloodstream. Evidence that tobacco carcinogens can bind to gastric mucosal DNA come from studies showing smokers to have significantly higher levels of smoking-related DNA adducts than non-smokers,92 and significantly higher levels of benzo(a)pyrene-DNA adducts in gastric tumors compared to normal tissue.93 Tobacco smoking may promote stomach carcinogenesis by causing mucosal injury through increasing gastric acid and pepsin secretion94, 95 or reflux of duodenal bile salts,96 or by depleting the concentrations of antioxidants in gastric juice or plasma.97, 98 Further research is needed to clarify the role of tobacco smoking and tobacco carcinogens in the complex web of dietary, infectious and host susceptibility factors important in stomach cancers of distinct topographic and histologic subtypes.

Our study was unable to differentiate between death due to tumors of the gastric cardia or non-cardia. Assuming that the distribution of stomach cancers by anatomical subsite in CPS II is similar to that in the US general population, we expect that half of the stomach cancer deaths in men and a smaller proportion in women resulted from tumors of the gastric cardia.17 Based on the consistently higher cigarette smoking risk estimates for gastric cardia than non-cardia tumors in case-control studies, CPS II results likely underestimated the true association between tobacco use and gastric cardia tumors. CPS II estimates also may have underestimated the true risk associated with continuing tobacco use since some current users at study enrollment may have quit over the follow-up period. The lack of updated tobacco use information during the follow-up period also weakens our ability to evaluate dose-response by smoking intensity or duration because current heavy smokers at study enrollment may discontinue or reduce tobacco consumption over time. The strengths of our study lie in the detailed information on the use of multiple types of tobacco products and covariates and on its large size that allowed us to examine the exclusive use of different tobacco products.

Worldwide, it has been estimated66 that the smoking-attributable proportion of stomach cancers is 11% among men and 4% among women in developing countries and 17% among men and 11% among women in developed countries. Based on CPS II results, we estimate that 28% of stomach cancer deaths in US men and 14% in women are attributable to tobacco use. The proportion of incident gastric cancers attributable to tobacco smoking has been estimated to be 20% in Poland52 and 31% in India.99 Adding stomach cancer to the list of cancers caused by tobacco would increase the total number of smoking-attributable deaths by at least 84,000 per year worldwide,66 not accounting for recent increases in smoking prevalence or the expected rise in stomach cancer incidence due to aging in the developing world.6

Tobacco use, particularly cigarette and cigar smoking, is associated with increased stomach cancer mortality in this large cohort of US adults. Results from this and other studies are consistent with a causal role of prolonged tobacco use in stomach cancer incidence and mortality in men and women and support reconsidering stomach cancer as a tobacco-related cancer.

POSTSCRIPT

  1. Top of page
  2. Abstract
  3. MATERIAL AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. POSTSCRIPT
  7. Acknowledgements
  8. REFERENCES

Stomach cancer was upgraded to a cancer for which sufficient evidence exists to infer a causal relationship with tobacco by the International Agency for Research on Cancer in its Review of Tobacco conducted in June 2002.

Acknowledgements

  1. Top of page
  2. Abstract
  3. MATERIAL AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. POSTSCRIPT
  7. Acknowledgements
  8. REFERENCES

Cancer Prevention Study II is funded by the American Cancer Society. A.C. is supported by the American Cancer Society and Public Health Service grant K07CA75062 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services.

REFERENCES

  1. Top of page
  2. Abstract
  3. MATERIAL AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. POSTSCRIPT
  7. Acknowledgements
  8. REFERENCES
  • 1
    The World Bank. Curbing the epidemic: governments and the economics of tobacco control. Tobacco Control 1999; 8: 196201.
  • 2
    World Health Organization. The World Health Report 1999: making a difference. Geneva: World Health Organization; 1999. http://www.who.int/whr/1999
  • 3
    Corrao MA, Guidon GE, Sharma N, Shokoohi DF. Tobacco control country profiles. Atlanta: American Cancer Society; 2000.
  • 4
    CDC. Surveillance for selected tobacco use behaviors—United States, 1900–1994. MMWR Morb Mortal Wkly Rep Surveill Summ 1994; 43: SS3.
  • 5
    CDC. Tobacco use among high school students—United States, 1997. MMWR Morb Mortal Wkly Rep Surveill Summ 1998; 47: 22933.
  • 6
    Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997; 349: 1498504.
  • 7
    Peto R, Lopez AD, Boreham J, Thun M, Heath C. Mortality from tobacco in developed countries: indirect estimation from national vital statistics. Lancet 1992; 339: 126878.
  • 8
    Malarcher AM, Chrismon JH, Giovino GA, Eriksen MP. Smoking-attributable mortality and years of potential life lost—United States, 1984. Editorial note—1997. MMWR Morb Mortal Wkly Rep Surveill Summ 1997; 46: 44451.
  • 9
    CDC. Smoking-attributable mortality and years of potential life lost—United States, 1984. MMWR Morb Mortal Wkly Rep Surveill Summ 1987; 36: 6937.
  • 10
    U.S. Department of Health and Human Services. Reducing the health consequences of smoking: 25 years of progress. A report of the Surgeon General. Washington DC: US Department of Health and Human Services, Public Health Service, Centers for Disease Control, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. DHHS Publication No. (CDC) 89-8411, 1989.
  • 11
    International Agency for Research on Cancer. Tobacco smoking. IARC Monographs on the valuation of the carcinogenic risk of chemicals to humans 38. Lyon: International Agency for Research on Cancer; 1986.
  • 12
    Parkin DM, Pisani P. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80: 82741.
  • 13
    Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999; 83: 1929.
  • 14
    Blaser MJ. Science, medicine and the future: Helicobacter pylori and gastric diseases. Br Med J 1998; 316: 150710.
  • 15
    Blaser MJ. Hypothesis: The changing relationships of Helicobacter pylori and humans: implications for health and disease. J Infect Dis 1999; 179: 152330.
  • 16
    Parsonnet J. Helicobacter pylori and gastric adenocarcinoma. In: ParsonnetJ, ed. Microbes and malignancy. New York: Oxford University Press; 1999. 372408.
  • 17
    Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 204953.
  • 18
    Botterweck AA, Schouten LJ, Volovics A, Dorant E, van den Brandt PA. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 2000; 29: 64554.
  • 19
    Chow WH, Blaser MJ, Blot WJ, Gammon MD, Vaughan TL, Risch HA, Perez-Perez GI, Schoenberg JB, Stanford JL, Rotterdam H, West AB, Fraumeni JF Jr. An inverse relation between cagA+ Strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 1998; 58: 58890.
  • 20
    Hansen S, Melby KK, Aase S, Jellum E, Vollset SE. Helicobacter pylori infection and risk of cardia cancer and non-cardia gastric cancer. Scand J Gastroenterol 1999; 34: 35360.
  • 21
    Gammon MD, Schoenberg JB, Ahsan H, Risch HA, Vaughan TL, Chow WH, Rotterdam H, West AB, Dubrow R, Stanford JL, Mayne ST, Farrow DC, Niwa S, Blot WJ, Fraumeni JF. Tobacco, alcohol and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1997; 89: 127784.
  • 22
    Kahn HA. The Dorn Study of smoking and mortality among US veterans: report on eight and one-half years of observation. Natl Cancer Inst Monogr 1966; 19: 1125.
  • 23
    Doll R, Peto R. Mortality in relation to smoking: 20 years' observation on male British doctors. Br Med J 1976; 2: 152536.
  • 24
    Kono S, Ikeda M, Tokudome S, Nishizumi M, Kuratsune M. Cigarette smoking, alcohol and cancer mortality: a cohort of male Japanese physicians. Jpn J Cancer Res 1987; 78: 13238.
  • 25
    Nomura A, Grove JS, Stemmermann GN, Severson RK. A Prospective study of stomach cancer and its relation to diet, cigarettes and alcohol consumption. Cancer Res 1990; 50: 62731.
  • 26
    Kneller RW, McLaughlin JK, Bjelke E, Schuman LM, Blot WJ, Wacholder S, Gridley G, CoChien HT, Fraumeni JF. A cohort study of stomach cancer in a high-risk American population. Cancer 1991; 68: 6728.
  • 27
    Kato I, Tominaga S, Matsumoto K. A prospective study of stomach cancer among a rural Japanese population: a 6-year survey. Jpn J Cancer Res 1992; 83: 56875.
  • 28
    Tverdal A, Thelle D, Stensvold I, Leren P, Bjartveit K. Mortality in relation to smoking history: 13 years' follow-up of 68,000 Norwegian men and women 35–49 years. J Clin Epidemiol 1993; 46: 47587.
  • 29
    Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years' observations on male British doctors. Br Med J 1994; 309: 90111.
  • 30
    McLaughlin JK, Hrubec Z, Blot WJ, Fraumeni JF. Smoking and cancer mortality among US Veterans: a 26-year follow-up. Int J Cancer 1995; 60: 1903.
  • 31
    Mizoue T, Tokui N, Nishisaka K, Nishisaka SI, Ogimoto I, Ikeda M, Yoshimura T. Prospective study on the relation of cigarette smoking with cancer of the liver and stomach in an endemic region. Int J Epidemiol 2000; 29: 2327.
  • 32
    You WC, Zhang L, Gail MH, Chang YS, Liu WD, Ma JL, Li JY, Jing ML, Hu YR, Yang CS, Blaser MJ, Correa P, Blot WJ, Fraumeni JF, Xu GW. Gastric dysplasia and gastric cancer: Helicobacter pylori, serum vitamin C and other risk factors. J Natl Cancer Inst 2000; 92: 160712.
  • 33
    Correa P, Fontham E, Pickle LW, Chen V, Lin Y, Haenszel W. Dietary determinants of gastric cancer in South Louisiana inhabitants. JNCI 1985; 75: 64554.
  • 34
    You WC, Blot WJ, Chang YS, Ershow AG, Yang ZT, AN Q, Henderson B, Xu GW, Fraumeni JF, Wang TG. Diet and high risk of stomach cancer in Shandong, China. Cancer Res 1988; 48: 351823.
  • 35
    Ferraroni M, Negri E, La Vecchia C, D'Avanzo B, Franceschi S. Socioeconomic indicators, tobacco and alcohol in the aetiology of digestive tract neoplasms. Int J Epidemiol 1989; 18: 5562.
  • 36
    Wu-Williams AH, Yu MC, Mack TM. Life-style, workplace and stomach cancer by subsite in young men of Los Angeles County. Cancer Res 1990; 50: 256976.
  • 37
    Kato I, Tominaga S, Ito Y, Kobayashi S, Yoshii Y, Matsuura A, Kameya A, Kano T. A comparative case-control analysis of stomach cancer and atrophic gastritis. Cancer Res 1990; 50: 655964.
  • 38
    Yu GP, Hsieh CC. Risk factors for stomach cancer: a population-based case-control study in Shanghai. Cancer Causes Control 1991; 2: 16974.
  • 39
    Saha SK, Smoking habits and carcinoma of the stomach: a case-control study. Jpn J Cancer Res 1991; 82: 497502.
  • 40
    Kabat GC, Ng SKC, Wynder EL. Tobacco, alcohol intake and diet in relation to adenocarcinoma of the esophagus and gastric cardia. Cancer Causes Control 1993; 4: 12332.
  • 41
    Jȩdrychowski W, Boeing H, Wahrendorf J, Popiela T, Tobiasz-Adamczyk B, Kulig J. Vodka consumption, tobacco smoking and risk of gastric cancer in Poland. Int J Epidemiol 1993; 22: 60613.
  • 42
    Hansson LE, Baron J, Nyrén O, Bergstrom R, Wolk A, Adami HO. Tobacco, alcohol and the risk of gastric cancer. A population-based case-control study in Sweden. Int J Cancer 1994; 57: 2631.
  • 43
    Brown LM, Silverman DT, Pottern LM, Schoenberg JB, Greenberg RS, Swanson GM, Liff JM, Schwartz AG, Hayes RB, Blot WJ, Hoover RN. Adenocarcinoma of the esophagus and esophagogastric junction in white men in the United States: alcohol, tobacco and socioeconomic factors. Cancer Causes Control 1994; 5: 33340.
  • 44
    Guo W, Blot WJ, Li JY, Taylor PR, Liu BQ, Wang W, Wu YP, Zheng W, Dawsey SM, Li B, Fraumeni JF. A nested case-control study of oesophageal and stomach cancers in the Linxian Nutrition Intervention Trial. Int J Epidemiol 1994; 23: 44450.
  • 45
    Inoue M, Tajima K, Hirose K, Kuroishi T, Gao CM, Kitoh T. Life-style and subsite of gastric cancer—joint effect of smoking and drinking habits. Int J Cancer 1994; 56: 4949.
  • 46
    Vaughn TL, Davis S, Kristal A, Thomas DB. Obesity, alcohol and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol Biomark Prev 1995; 4: 8592.
  • 47
    Ji BT, Chow WH, Yang G, McLaughlin JK, Gao RN, Zheng W, Shu XO, Jin F, Fraumeni JF, Gao YT. The influence of cigarette smoking, alcohol and green tea consumption on the risk of carcinoma of the cardia and distal stomach in Shanghai, China. Cancer 1996; 77: 244957.
  • 48
    Zhang ZF, Kurtz RC, Sun M, Karpeh M, Yu GP, Gargon N, Fein JS, Georgopoulos SK, Harlap S. Adenocarcinomas of the esophagus and gastric cardia: medical conditions, tobacco, alcohol and socioeconomic factors. Cancer Epidemiol Biomark Prev 1996; 5: 7618.
  • 49
    De Stefani E, Boffetta P, Carzoglio J, Mendilaharsu S, Deneo-Pellegrini H. Tobacco smoking and alcohol drinking as risk factors for stomach cancer: a case-control study in Uruguay. Cancer Causes Control 1998; 9: 3219.
  • 50
    Ye W, Ekstrom AM, Hansson LE, Bergstrom R, Nyrén O. Tobacco, alcohol and the risk of gastric cancer by sub-site and histologic type. Int J Cancer 1999; 83: 2239.
  • 51
    Inoue M, Tajima K, Yamamura Y, Hamajima N, Hirose K, Nakamura S, Kodera Y, Kitao T, Tominaga S. Influence of habitual smoking on gastric cancer by histologic subtype. Int J Cancer 1999; 81: 3943.
  • 52
    Chow WH, Swanson CA, Lissowska J, Groves FD, Sobin LH, Nasierowska-Guttmejer A, Radziszewski J, Regula J, Hsing AW, Jagannatha S, Zatonski W, Blot WJ. Risk of stomach cancer in relation to consumption of cigarettes, alcohol, tea and coffee in Warsaw, Poland. Int J Cancer 1999; 81: 8716.
  • 53
    Zaridze D, Borisova E, Maximovitch D, Chkhikvadze V. Alcohol consumption, smoking and risk of gastric cancer: case-control study from Moscow, Russia. Cancer Causes Control 2000; 11: 36371.
  • 54
    Muñoz N, Plummer M, Vivas J, Moreno V, De Sanjose, S, Lopez G, Oliver W. A case-control study of gastric cancer in Venezuela. Int J Cancer 2001; 93: 41723.
  • 55
    Lagergren J, Bergstrom R, Lindgren A, Nyrén O. The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. Int J Cancer 2000; 85: 3406.
  • 56
    Wu AH, Wan P, Bernstein L. A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinoma of the stomach and esophagus (United States). Cancer Causes Control 2001; 12: 72132.
  • 57
    Cartensen JM, Pershagen G, Eklund G. Mortality in relation to cigarette and pipe smoking: 16 years' observation of 25,000 Swedish men. J Epidemiol Comm Health 1987; 41: 16672.
  • 58
    Engeland A, Andersen A, Haldorsen T, Tretli S. Smoking habit and risk of cancers other than lung cancer: 28 years' follow-up of 26,000 Norwegian men and women. Cancer Causes Control 1996; 7: 497506.
  • 59
    Nordlund LA, Cartensen JM, Pershagen G. Cancer incidence in female smokers: a 26-year follow-up. Int J Cancer 1997; 73: 62528.
  • 60
    Jȩdrychowski W, Wahrendorf J, Popiela T, Rachtan J. A case-control study of dietary factors and stomach cancer risk in Poland. Int J Cancer 1986; 37: 83742.
  • 61
    Boeing H, Frentzel-Beyme R, Berger M, Berndt V, Gores W, Korner M, Lohmeier R, Menarcher A, Mannl, HFK, Meinhardt M, Muller R, Ostermeier H, Paul F, Schwemmle K, Wagner KH, Wahrendorf J. Case-control study on stomach cancer in Germany. Int J Cancer 1991; 47: 85864.
  • 62
    Agudo A, Gonzalez CA, Marcos G, Sanz M, Saigi E, Verge J, Boleda M, Ortego J. Consumption of alcohol, coffee and tobacco and gastric cancer in Spain. Cancer Causes Control 1992; 3: 13743.
  • 63
    Palli D, Bianchi S, Decarli A, Cipriani F, Avellini C, Cocco P, Falcini F, Puntoni R, Russo A, Vindigni C, Fraumeni JF, Blot WJ, Buiatti E. A case-control study of cancers of the gastric cardia in Italy. Br J Cancer 1992; 65: 2636.
  • 64
    Hoshiyama Y, Sasaba T. A case-control study of stomach cancer and its relation to diet, cigarettes and alcohol consumption in Saitama Prefecture, Japan. Cancer Causes Control 1992; 3: 4418.
  • 65
    Doll R. Cancers weakly related to smoking. Br Med Bull 1996; 52: 3549.
  • 66
    Trédaniel J, Boffetta P, Buiatti E, Saracci R, Hirsch A. Tobacco smoking and gastric cancer: review and meta-analysis. Int J Cancer 1997; 72: 56573.
  • 67
    Calle EE, Terrell DD. Utility of the National Death Index for ascertainment of mortality among Cancer Prevention Study II participants. Am J Epidemiol 1993; 137: 23541.
  • 68
    World Health Organization (WHO). International Classification of Disease. Manual of the International Statistical Classification of Diseases, Injuries and Causes of Death. Vol. 1, 9th Revision. Geneva (Switzerland): WHO; 1997.
  • 69
    McCullough ML, Robertson AS, Jacobs EJ, Chao A, Calle EE, Thun MJ. A prospective study of diet and stomach cancer mortality in US men and women. Cancer Epidemiol Biomark Prev 2001; 10: 12015.
  • 70
    Jacobs EJ, Connell CJ, McCullough ML, Chao A, Jonas CR, Rodriguez C, Calle EE, Thun MJ. Use of supplemental vitamin C, vitamin E and multivitamins and stomach cancer mortality in the Cancer Prevention Study II cohort. Cancer Epidemiol Biomark Prev 2002; 11: 3541.
  • 71
    Nomura A. Stomach cancer. In: SchottenfeldD, FraumeniJF, eds. Cancer epidemiology and prevention, 2nd ed. New York: Oxford University Press; 1996. 70724.
  • 72
    World Cancer Research Fund and the American Institute for Cancer Research. Stomach. In: Food, Nutrition and the Prevention of Cancer: a Global Perspective. Washington DC: American Institute for Cancer Research; 1997. 14875.
  • 73
    Cox DR. Regression models and life table. J R Stat Soc 1972; 34: 187220.
  • 74
    Breslow NE, Day NE. Statistical methods in cancer research. Vol. I. The analysis of case-control studies. IARC Sci Publ 1980; 32: 5338.
  • 75
    Greenland S, Rothman KJ. Introduction to stratified analysis. In: RothmanKJ, GreenlandS, eds. Modern epidemiology, 2nd ed. Philadelphia: Lippincott-Raven; 1998. 25379.
  • 76
    SAS. SAS/STAT User's Guide, Version 8, Volumes 1–3. Cary, North Carolina: SAS Institute Inc.; 2000.
  • 77
    Gerlach KK, Cummings KM, Hyland A, Gilpin EA, Johnson MD, Pierce JP. Trends in cigar consumption and smoking prevalence. In: BurnsD, CummingsKM, HoffmanD, eds. Cigars: health effects and trends, smoking and tobacco control monograph No. 9. Bethesda: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute: NIH Publication No. 98-4302; 1998.
  • 78
    Burns DM. Cigar smoking: overview and current state of the science. In: BurnsD, CummingsKM, HoffmanD, eds. Cigars: health effects and trends, smoking and tobacco control monograph No. 9. Bethesda: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute: NIH Publication No. 98-4302; 1998.
  • 79
    Brunnemann KD, Hoffmann D. Chemical composition of smokeless tobacco products. In: Smokeless tobacco or health: an international perspective, smoking and tobacco control monograph No. 2. USDHHS NIH NCI, Bethesda, MD, U.S. Department of Health and Human Services, National Institutes of Health: NIH Publication No. 93-3461; 1993.
  • 80
    Hecht SS. DNA adduct formation from tobacco-specific N-nitrosamines. Mutat Res 1999; 424: 12742.
  • 81
    Hecht SS, Carmella SG, Murphy SE, Goiles PG, Chung FL. Carcinogen biomarkers related to smoking and upper aerodigestive tract cancer. J Cell Biochem 1993; 17 (Suppl): 2735.
  • 82
    Siman JH, Forsgren A, Berglund G, Floren CH. Tobacco smoking increases the risk for gastric adenocarcinoma among Helicobacter pylori-infected individuals. Scand J Gastroenterol 2001; 36: 20813.
  • 83
    Cover TL, Vaughn SG, Cao P, Blaser M. Potentiation of Helicobacter pylori vacuolating toxin activity by nicotine and other weak bases. J Infectious Dis 1992; 166: 10738.
  • 84
    Shimoyama T, Everett SM, Fukuda S, Axon ATR, Dixon MF, Crabtree JE. Influence of smoking and alcohol on gastric chemokine mRNA expression in patients with Helicobacter pylori infection. J Clin Pathol 2001; 54: 3324.
  • 85
    Stemmermann GN, Nomura AM, Chyou PH, Hankin J. Impact of diet and smoking on risk of developing intestinal metaplasia of the stomach. Dig Dis Sci 1990; 35: 4338.
  • 86
    Kneller RW, You WC, Chang YS, Liu WD, Zhang L, Zhao L, Xu GW, Fraumeni JF, Blot WJ. Cigarette smoking and other risk factors for progression of precancerous stomach lesions. J Natl Cancer Inst 1992; 84: 12616.
  • 87
    Jȩdrychowski W, Popiela T, Drews M, Gabryelewicz A, Marlicz K, Misiunia P, Wajda Z, Matyja A, Nowak K, Ramroth H, Wahrendon J. Effect of Helicobacter pylori infection, smoking and dietary habits on the occurrence of antrum intestinal metaplasia. Clinico-epidemiological study in Poland. Pol J Pathol 1999; 50: 28995.
  • 88
    Russo A, Maconi G, Spinelli P, Felice GD, Eboli M, Andreola S, Ravagnani F, Settesoldi D, Ferrari D, Lombardo C, Bertario L. Effect of lifestyle, smoking and diet on development of intestinal metaplasia in H. pylori-positive subjects. Am J Gastroenterol 2001; 96: 14028.
    Direct Link:
  • 89
    Iwata F, Zhang XY, Leung FW. Aggravation of gastric mucosal lesions in rat stomach by tobacco cigarette smoke. Dig Dis Sci 1995; 40: 111824.
  • 90
    Hoffman D, Hoffman I. The changing cigarette, 1950–1995. J Toxicol Environ Health 1997; 50: 30764.
  • 91
    Hoffman D, Hoffman I. Chemistry and toxicology. In: BurnsD, CummingsKM, HoffmanD, eds. Cigars: health effects and trends, smoking and tobacco control monograph No. 9. Bethesda: US Department of Health and Human Services, National Institutes of Health, National Cancer Institute: NIH Publication No. 98-4302; 1998.
  • 92
    Dyke GW, Craven JL, Hall R, Garner RC. Smoking-related DNA adducts in human gastric cancers. Int J Cancer 1992; 52: 84750.
  • 93
    Lee BM, Jang JJ, Kim HS. Benzo[a]pyrene diol-epoxide-I-DNA and oxidative DNA adducts associated with gastric adenocarcinoma. Cancer Lett 1998; 125: 618.
  • 94
    Endoh K, Leung FW. Effects of smoking and nicotine on the gastric mucosa: a review of clinical and experimental evidence. Gastroenterology 1994; 107: 86478.
  • 95
    Lanas A, Hirschowitz BI. Influence of smoking on basal and on vagally and maximally stimulated gastric acid and pepsin secretion. Scand J Gastroenterol 1992; 27: 20812.
  • 96
    Moller-Lissner SA. Bile reflux is increased in cigarette smokers. Gastroenterology 1986; 90: 12059.
  • 97
    Jarosz M, Dzieniszewski J, Dabrowska-Ufnizrz E, Wartanowicz M, Ziemlanski S. Tobacco smoking and vitamin C concentration in gastric juice in healthy subjects and patients with Helicobacter pylori infection. Euro J Cancer Prev 2000; 9: 4238.
  • 98
    Phull PS, Price AB, Thorniley MS, Green JG, Jacyna MR. Plasma free radical activity and antioxidant vitamin levels in dyspeptic patients: correlation with smoking and Helicobacter pylori infection. European J Gastroenterol Hep 1998; 10: 5738.
  • 99
    Gajalakshmi CK, Shanta V. Lifestyle and risk of stomach cancer: a hospital-based case-control study. Int J Epidemiol 1996; 25: 114653.